Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
IPO Year: 2021
Exchange: NYSE
Website: ginkgobioworks.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2024 | Neutral → Sell | BTIG Research | |
| 5/10/2024 | Mkt Perform → Underperform | William Blair | |
| 11/14/2023 | $3.50 → $2.50 | Outperform → Mkt Perform | Raymond James |
| 11/9/2023 | Buy → Neutral | BTIG Research | |
| 6/2/2023 | $3.00 → $1.25 | Neutral → Sell | Goldman |
| 5/11/2023 | Outperform → Mkt Perform | William Blair | |
| 11/29/2022 | $6.00 | Buy | Berenberg |
| 10/4/2022 | $5.00 | Equal-Weight | Morgan Stanley |
| 5/18/2022 | $3.00 | Neutral → Underperform | BofA Securities |
| 3/2/2022 | $12.00 | Outperform | Cowen |
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13D/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13D/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information will be available at investors.ginkgobioworks.com.
BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of a previously announced partnership with Merck, known as MSD outside of the United States and Canada, focused on improving biologic manufacturing. As part of this milestone completion, Ginkgo will receive a research milestone payment of $9 million in cash. The two companies will now move on to the second stage of this partnership, which will be focused on continuing to improve the
Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON, Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investor
BOSTON and CHESTERFIELD, Mo., Sept. 24, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, announced its new partnership with NOVUS International, an innovator and leader in intelligent nutrition, to develop advanced feed additives designed to meet the evolving needs of the animal agriculture industry. By utilizing Ginkgo Enzyme Services, NOVUS will work with Ginkgo to build more efficient enzymes that can be produced cost-effectively. With the agricultural sector facing heightened volatility, in
BOSTON, Sept. 18, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient. Ginkgo Datapoints is specialized in generating large, high-quality biological datasets with a fast turnaround time and at a competitive price per datapoint with a streamlined deal structure. Ginkgo Datapoints will launch with several data generation products this Fall including protein characterization and functional genomics.
Protein large language model (LLM) designed to help enterprises accelerate drug development coming to Google Cloud's Vertex AI Model Garden soon; one of the first-of-its-kind in the industryModel API programmable interface now available for individual scientists and researchers to quickly test and advance workBOSTON, Sept. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced two new offerings that will make it easier for pharmaceutical and biotech companies to develop new medicines, building on the partnership announced with Google Cloud last year. The first launch is one of the first-
BOSTON, Sept. 4, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", or the ", Company", ))), which is building the leading platform for cell programming and biosecurity, today announced that it had received a letter from the New York Stock Exchange ("NYSE") on September 3, 2024 stating that because Ginkgo's Class A common stock had a closing bid price at or above $1.00 on the last day of August and the Company's 30-day trading average closed above $1.00, Ginkgo had regained compliance with Section 802.01C of the NYSE Listed Company Manual. As previously
BOSTON, Aug. 30, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that Chief Financial Officer, Mark Dmytruk, is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6 at 11:30 a.m. ET. Further details, a webcast link, and a replay of the fireside chat will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events. About Ginkgo Bioworks Ginkgo Bioworks is
Ginkgo provides update on its restructuring process including estimated annualized cost savings of over $85 million from reduction in force BOSTON, Aug. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", ))), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2024. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at investors.ginkgobioworks.com. Second Qu
Special meeting to take place virtually on August 14, 2024 at 4:00 pm ET BOSTON, Aug. 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", ))), which is building the leading platform for cell programming and biosecurity, will be holding a special meeting of shareholders virtually on August 14, 2024 at 4:00 pm ET to vote to permit, at the discretion of the Board of Directors, a reverse stock split of the issued and outstanding shares of Class A common stock and Class B common stock in a range of not less than one-for-twenty (1:20) and not more than one-for-forty (1:40), with the final ratio to be determined by the Board of Directors. Shareholders will also vote to app
Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON, May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with key Japanese businesses and encourage the use of synthetic biology to develop sustainable production processes.
Ginkgo customers will now have access to IdeeLab's local strain discovery capabilities, as well as the ability to manufacture next-generation products in IdeeLab's manufacturing facilities PIRACICABA, Brazil, April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, to join the Ginkgo Technology Network. The Ginkgo Technology Netw
The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric's global network BOSTON and SAN DIEGO, Jan. 15, 2024 /PRNewswire/ -- Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally.
Mr. Coen brings over 30 years of public accounting and corporate finance leadership experience, most recently as Corporate Vice President and Corporate Controller at Charles River Laboratories Marie Fallon to step down as CAO effective May 15, 2023 BOSTON, May 5, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", or the ", Company", ))), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Steven P. Coen, CPA, a seasoned finance executive with more than 30 years of public accounting and corporate finance leadership experience, as Chief Accounting Officer ("CAO"), effective May 15, 2023. Most recently, Mr. Coen
Newest foundry increases capacity in biopharmaceuticals, biomanufacturing and general mammalian programming for therapeutic applications BOSTON, Jan. 6, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced the opening of Bioworks7, the latest expansion of its biological engineering foundry. With this new space, Ginkgo increases its capacity and capabilities to serve its partners in the spaces of cell and gene therapy, biomanufacturing and general mammalian programming for therapeutic applications and new biopharmaceutical modalities. Ginkgo's foundry automates and scales the process of organism engineeri
BOSTON, Sept. 1, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), the leading horizontal platform for cell programming, today announced that Behzad Mahdavi, Ph.D., MBA, has joined as senior vice president of biopharma manufacturing and life sciences tools. In this new role, Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities. Dr. Mahdavi brings more than 20 years of experience in developing and leading innovative patient-centric growth strategies in challenging environments in the biopharmaceutical, cell and gene therapy, personalized medicine and life sciences sectors.
Health and wellness industry veteran will lead the company to scale sustainable bioactives using plant cell technology instead of agriculture BOSTON, Aug. 24, 2022 /PRNewswire/ -- Ayana Bio, the plant cell technology company making sustainable bioactives for consumer products, today announced the appointment of Frank Jaksch as the company's chief executive officer. Jaksch founded, was the longtime CEO and presently serves as Board Chair of health and wellness company ChromaDex, manufacturer of popular NAD product, Tru Niagen (NASDAQ:CDXC).
BOSTON, Aug. 4, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), the leading horizontal platform for cell programming, today announced that Kathy Hopinkah Hannan, PhD, CPA has joined its Board of Directors, effective August 2, 2022. Dr. Hannan brings over thirty years of experience as a senior C-Suite executive, corporate advisor, independent board director and strategist leading significant operations and high priority initiatives. "As a pioneer in synthetic biology, Ginkgo Bioworks is undertaking critical work to make biology easier to engineer and to enable a more sustainab
10-Q - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
25-NSE - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
DEFA14A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
10-Q - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
8-K/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
DEF 14A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information will be available at investors.ginkgobioworks.com.
Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON, Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investor
Ginkgo provides update on its restructuring process including estimated annualized cost savings of over $85 million from reduction in force BOSTON, Aug. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", ))), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2024. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at investors.ginkgobioworks.com. Second Qu
Presentation and Q&A session scheduled for post-market on Thursday, August 8, 2024 BOSTON, Aug. 1, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", ))), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkg
Ginkgo announces several initiatives to accelerate path to Adjusted EBITDA breakeven by end of 2026 Initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-2025, with anticipated substantial reduction occurring in 2024 BOSTON, May 9, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", ))), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2024. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.
Presentation and Q&A session scheduled for post-market on Thursday, May 9, 2024 BOSTON, May 2, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", ))), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobiowor
USA News Group Commentary VANCOUVER, BC, April 25, 2024 /PRNewswire/ -- Across several sectors the use of artificial intelligence (AI) is making a huge impact, with healthcare emerging as possibly receiving the largest boost. According to a new research report from analysts at Mordor Intelligence, the market for artificial intelligence in health care is set to explode at a CAGR of 42.20% through 2029. As the tech sector races to provide the market with solutions, several companies are emerging as leaders in aiding the healthcare sector, including Avant Technologies Inc. (OTC:AVAI), Microsoft Corporation (NASDAQ:MSFT) (NEO:MSFT), Health Catalyst, Inc. (NASDAQ:HCAT), Ginkgo Bioworks Holdings,
BOSTON, April 11, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of AgBiome's platform assets, including over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, and relevant functional data and metadata, as well as AgBiome's development pipeline. These assets will be integrated into Ginkgo Ag Biologicals Services, established with the acquisition of a Bayer agricultural biologicals R&D facility in 2022, and will expand Ginkgo's proprietary unified metagenomics database. Combined, this creates one of the deepest and most advanced ag biological dis
BOSTON, April 2, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their chimeric antigen receptor (CAR) and switch receptor libraries. Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases. In contrast to legacy cell therapy design, the company uses a combinatorial approach to build and screen cell therapy components that work in
BOSTON, Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Patch Biosciences, which has built an AI platform for sequence design that enables more effective, specific, and durable genetic medicines and was backed by Andreessen Horowitz (a16z) Bio + Health, Casdin Capital, and S32. The acquisition is intended to strengthen Ginkgo's Gene Therapy Services, Cell Therapy Services, and RNA Therapeutics Services. Ginkgo does not have a product portfolio or drug pipe
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
BTIG Research downgraded Ginkgo Bioworks from Neutral to Sell
William Blair downgraded Ginkgo Bioworks from Mkt Perform to Underperform
Raymond James downgraded Ginkgo Bioworks from Outperform to Mkt Perform and set a new price target of $2.50 from $3.50 previously
BTIG Research downgraded Ginkgo Bioworks from Buy to Neutral
Goldman downgraded Ginkgo Bioworks from Neutral to Sell and set a new price target of $1.25 from $3.00 previously
William Blair downgraded Ginkgo Bioworks from Outperform to Mkt Perform
Berenberg initiated coverage of Ginkgo Bioworks with a rating of Buy and set a new price target of $6.00
Morgan Stanley initiated coverage of Ginkgo Bioworks with a rating of Equal-Weight and set a new price target of $5.00
BofA Securities downgraded Ginkgo Bioworks from Neutral to Underperform and set a new price target of $3.00
Cowen resumed coverage of Ginkgo Bioworks with a rating of Outperform and set a new price target of $12.00
On Wednesday, Cathie Wood-led Ark Invest made a notable move by offloading a significant number of shares in Tesla Inc (NASDAQ:TSLA), despite the recent rally driven by the company’s impressive second-quarter delivery numbers. The Tesla Trade Ark Invest reduced its stake in Tesla across its ARK Innovation ETF (NYSE:ARKK), selling 13,213 shares. This transaction came as a surprise, given that Tesla’s shares had recently soared 10.20% on Tuesday, marking the best intraday session since late April. Notably, on Tuesday, Ark Invest sold Tesla shares worth $14.5 million. The boost was primarily driven by the Elon Musk-led company’s second-quarter performance. Tesla reported 443,956 delive
On Wednesday, Cathie Wood-led Ark Invest made significant trades in Roku Inc (NASDAQ:ROKU) and Coinbase Global Inc (NASDAQ:COIN), amidst a volatile market. These prominent trades were part of a series of transactions carried out by Ark’s various ETFs. The ROKU Trade ARK Innovation ETF (NYSE:ARKK) and ARK Next Generation Internet ETF (NYSE:ARKW) bought 127,540 shares in Roku Inc. The ARKK fund acquired 106,420 shares, while the ARKW fund added 21,120 shares. The transaction amounted to $7.3 million. On Wednesday, Roku shares closed 4.6% higher at $57.16 in the regular session. Notably, Wood’s firm purchased $5.3 million worth of Roku shares a day earlier. These moves come amidst Roku
BTIG analyst Mark Massaro maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and lowers the price target from $0.5 to $0.2.
On Tuesday, June 25, 2024, Cathie Wood-led Ark Invest made significant trades in NVIDIA Corp (NASDAQ:NVDA) and Roku Inc (NASDAQ:ROKU), amidst considerable market volatility. These trades were part of a series of transactions carried out by Ark’s various ETFs. The NVIDIA Trade The firm’s ARK Autonomous Technology & Robotics ETF (BATS:ARKQ) sold 33,834 NVIDIA shares on Tuesday. The transaction was valued at $4.3 million. On the day, Nvidia shares closed 6.8% higher at $126.09. This move comes in the wake of a significant market cap loss for the tech giant, which saw a $550 billion drop since Thursday. Despite this, NVIDIA managed to rebound by over 6% on Tuesday, regaining its positio
As previously announced, on May 9, 2024, in connection with the Company’s multi-year plan to reduce operational expenditures, management approved a plan for restructuring actions, including an expected reduction in labor expenses of at least 25% and a planned consolidation of certain of its facilities. On June 17, 2024, the Company, with approval of its Board of Directors, began implementing its restructuring plan with headcount reductions, which the Company expects to result in a total reduction of at least 35% of the workforce when all impacted employees have departed. The Company continues to expect the headcount reductions to be substantially completed in 2025, subject to local laws.
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday. Shares of ResMed Inc. (NYSE:RMD) fell sharply during Monday's session following sleep apnea data from Lilly. Citigroup analyst Mathieu Chevrier downgraded ResMed from Buy to Neutral. ResMed shares dipped 10.4% to $184.35 on Monday. Here are some other big stocks recording gains in today’s session. Molecular Partners AG (NASDAQ:MOLN) shares dipped 22.6% to $7.43. Cryoport, Inc. (NASDAQ:CYRX) fell 19.9% to $7.77. Cryoport announced a strategic partnership with Minaris Regenerative Medicine for cell and gene therapies advancement. BridgeBio Pharma, Inc. (NASDAQ:BBIO) dipped 19.2% to $22.1
Cathie Wood‘s flagship ARK Innovation ETF (NYSE:ARKK) has been navigating through significant losses, showcasing the challenges faced by some of its major holdings. What Happened: Since its peak in February 2021, the fund has experienced substantial losses. The ARKK ETF has declined by 72% since its peak on Feb. 19, 2021. During this period, the Nasdaq 100, its primary benchmark, has surged by 39%, reaching record highs. Year-to-date, the ARKK ETF has decreased by 15%, while the Nasdaq 100 has increased by 12%. Data from Cathie’s Ark, a platform monitoring ARK Invest’s ETFs’ daily trades, reveals that only Tesla Inc (NASDAQ:TSLA), among ARKK’s top 10 stock holdings, has shown a positi
Ginkgo Bioworks Holdings's (NYSE:DNA) short percent of float has risen 7.94% since its last report. The company recently reported that it has 289.73 million shares sold short, which is 23.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.39 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Sh